Febuxostat, an XOD inhibitor, attenuates stress-induced hyperuricemia and inflammatory parameters, including TNF-α mRNA expression in the adipose tissue [43], indicating the involvement of uric acid in obesity-related inflammation. Here, TNF is linked to obesity disorder.